Abstract
Abstract
Purpose
The presurgical discrimination of IDH-mutant astrocytoma grade 4 from IDH-wildtype glioblastoma is crucial for patient management, especially in younger adults, aiding in prognostic assessment, guiding molecular diagnostics and surgical planning, and identifying candidates for IDH-targeted trials. Despite its potential, the full capabilities of DSC-PWI remain underexplored. This research evaluates the differentiation ability of relative-cerebral-blood-volume (rCBV) percentile values for the enhancing and non-enhancing tumor regions compared to the more commonly used mean or maximum preselected rCBV values.
Methods
This retrospective study, spanning 2016–2023, included patients under 55 years (age threshold based on World Health Organization recommendations) with grade 4 astrocytic tumors and known IDH status, who underwent presurgical MR with DSC-PWI. Enhancing and non-enhancing regions were 3D-segmented to calculate voxel-level rCBV, deriving mean, maximum, and percentile values. Statistical analyses were conducted using the Mann-Whitney U test and AUC-ROC.
Results
The cohort consisted of 59 patients (mean age 46; 34 male): 11 astrocytoma-4 and 48 glioblastoma. While glioblastoma showed higher rCBV in enhancing regions, the differences were not significant. However, non-enhancing astrocytoma-4 regions displayed notably higher rCBV, particularly in lower percentiles. The 30th rCBV percentile for non-enhancing regions was 0.705 in astrocytoma-4, compared to 0.458 in glioblastoma (p = 0.001, AUC-ROC = 0.811), outperforming standard mean and maximum values.
Conclusion
Employing an automated percentile-based approach for rCBV selection enhances differentiation capabilities, with non-enhancing regions providing more insightful data. Elevated rCBV in lower percentiles of non-enhancing astrocytoma-4 is the most distinguishable characteristic and may indicate lowly vascularized infiltrated edema, contrasting with glioblastoma’s pure edema.
Publisher
Springer Science and Business Media LLC
Reference44 articles.
1. WHO Classification of Tumours Editorial Board Central nervous system tumours [Internet] Lyon (France): International Agency for Research on Cancer; 2021 [cited 2023 Jul 13]. (WHO classification of tumours series, 5th ed.). https://tumourclassification.iarc.who.int/chapters/45
2. Mellinghoff IK, van den Bent MJ, Blumenthal DT et al (2023) Vorasidenib in IDH1- or IDH2-Mutant low-Grade Glioma. N Engl J Med. https://doi.org/10.1056/NEJMoa2304194
3. Mitchell D, Shireman JM, Dey M (2022) Surgical Neuro-Oncology. Neurol Clin 40:437–453. https://doi.org/10.1016/j.ncl.2021.11.003
4. Balana C, Castañer S, Carrato C et al (2022) Preoperative diagnosis and molecular characterization of Gliomas with Liquid Biopsy and Radiogenomics. Front Neurol 13:865171. https://doi.org/10.3389/fneur.2022.865171
5. Vagvala S, Guenette JP, Jaimes C, Huang RY (2022) Imaging diagnosis and treatment selection for brain tumors in the era of molecular therapeutics. Cancer Imaging 22:19. https://doi.org/10.1186/s40644-022-00455-5